| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 10, 905-912, Copyright © 1996 by The Federation of American Societies for Experimental Biology
RESEARCH COMMUNICATIONS |
M Sato, MK Rippy and HU Bryant
Department of Endocrine Research, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
For the first time, four well-characterized compounds from four distinct chemical classes were directly compared for efficacy and potency in hone, uteri, lipids, and adipose tissues in an ovariectomized model with 6 month old rats. Five weeks of oral dosing confirmed that ethynyl estradiol, tamoxifen, and raloxifene are potent inhibitors of the loss in volumetric bone mineral density (BMD, mg/cc) induced by ovariectomy, as measured by computed tomography. In the metaphysis of distal femora from ovariectomized rats, analysis showed a significant 12-20% decrease (P< 0.01) in the BMD. Linear regression analysis was used to calculate half-maximal efficacious doses for ethynyl estradiol ED(50) =0.04mg /kg, which was threefold more potent than tamoxifen, which in turn was threefold more potent than raloxifene, which was more efficacious than nafoxidine. In the uterus, raloxifene had minimal effects on the endometrium and smaller effects on uterine eosinophil peroxidase activity than nafoxidine, tamoxifen, or estrogen, respectively. Estrogen was the most potent in reducing cholesterol levels in ovariectomized rats, whereas tamoxifen and nafoxidine were more effective than raloxifene in blocking gain in body weight. Distinct compounds had advantages in the management of bone, uterine, serum cholesterol, and adipose tissues after ovariectomy. The distinct pattern of pharmacological effects may be best understood in terms of their respective chemical structure, specifically estrogens, benzothiophenes (raloxifene), dihydronapthylenes (nafoxidine), and triphenylethylenes (tamoxifen). These data point to advantages of separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus.
This article has been cited by other articles:
|
|
 |
|
  C. J. Mark, R. Tatchum-Talom, D. S. Martin, and K. M. Eyster Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1969 - R1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. I. Moreira, J. Custodio, A. Moreno, C. R. Oliveira, and M. S. Santos Tamoxifen and Estradiol Interact with the Flavin Mononucleotide Site of Complex I Leading to Mitochondrial Failure J. Biol. Chem., April 14, 2006; 281(15): 10143 - 10152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Helvering, R. Liu, N. H. Kulkarni, T. Wei, P. Chen, S. Huang, F. Lawrence, D. L. Halladay, R. R. Miles, E. M. Ambrose, et al. Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene Mol. Pharmacol., November 1, 2005; 68(5): 1225 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, D. Richard, and Y. Deshaies The Selective Estrogen Receptor Modulator Acolbifene Reduces Cholesterolemia Independently of Its Anorectic Action in Control and Cholesterol-Fed Rats J. Nutr., September 1, 2005; 135(9): 2225 - 2229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, K. Cianflone, and Y. Deshaies Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors J. Lipid Res., June 1, 2005; 46(6): 1285 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Althuis, K. S. Moghissi, C. L. Westhoff, B. Scoccia, E. J. Lamb, J. H. Lubin, and L. A. Brinton Uterine Cancer after Use of Clomiphene Citrate to Induce Ovulation Am. J. Epidemiol., April 1, 2005; 161(7): 607 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Cooke and A. Naaz Role of Estrogens in Adipocyte Development and Function Experimental Biology and Medicine, December 1, 2004; 229(11): 1127 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fitts, R. M. Klein, and C. A. Powers Comparison of Tamoxifen and Testosterone Propionate in Male Rats: Differential Prevention of Orchidectomy Effects on Sex Organs, Bone Mass, Growth, and the Growth Hormone-IGF-I Axis J Androl, July 1, 2004; 25(4): 523 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Z. Ke, G. L. Foley, H. A. Simmons, V. Shen, and D. D. Thompson Long-Term Treatment of Lasofoxifene Preserves Bone Mass and Bone Strength and Does Not Adversely Affect the Uterus in Ovariectomized Rats Endocrinology, April 1, 2004; 145(4): 1996 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Labrie, M. El-Alfy, L. Berger, C. Labrie, C. Martel, A. Belanger, B. Candas, and G. Pelletier The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women's Health? Endocrinology, November 1, 2003; 144(11): 4700 - 4706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats Endocrinology, May 1, 2003; 144(5): 2008 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhou, G. Turgeman, S. E. Harris, D. C. Leitman, B. S. Komm, P. V. N. Bodine, and D. Gazit Estrogens Activate Bone Morphogenetic Protein-2 Gene Transcription in Mouse Mesenchymal Stem Cells Mol. Endocrinol., January 1, 2003; 17(1): 56 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Galbiati, P. L. Caruso, G. Amari, E. Armani, S. Ghirardi, M. Delcanale, and M. Civelli Pharmacological Actions of a Novel, Potent, Tissue-Selective Benzopyran Estrogen J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cucinelli, L. Soranna, D. Romualdi, G. Muzj, S. Mancuso, and A. Lanzone The Effect of Raloxifene on Glyco-Insulinemic Homeostasis in Healthy Postmenopausal Women: A Randomized Placebo-Controlled Study J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4186 - 4192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Norris, D. Fan, A. Sherk, and D. P. McDonnell A Negative Coregulator for the Human ER Mol. Endocrinol., March 1, 2002; 16(3): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Galbiati, P. L. Caruso, G. Amari, E. Armani, S. Ghirardi, M. Delcanale, and M. Civelli J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 802 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. McDONNELL, C.-Y. CHANG, and J. D. NORRIS Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 16 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. BLUM and R. O. CANNON III Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Long, I. R. Cohen, C. L. Gries, J. K. Young, P. C. Francis, and C. C. Capen Proliferative Lesions of Ovarian Granulosa Cells and Reversible Hormonal Changes Induced in Rats by a Selective Estrogen Receptor Modulator Toxicol Pathol, October 1, 2001; 29(6): 719 - 726. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Long, I. R. Cohen, C. L. Gries, J. K. Young, P. C. Francis, and C. C. Capen Proliferative Lesions of Ovarian Granulosa Cells and Reversible Hormonal Changes Induced in Rats by a Selective Estrogen Receptor Modulator Toxicol Pathol, June 1, 2001; 29(4): 403 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 A. McDougal, M. Wormke, J. Calvin, and S. Safe Tamoxifen-induced Antitumorigenic/Antiestrogenic Action Synergized by a Selective Aryl Hydrocarbon Receptor Modulator Cancer Res., May 1, 2001; 61(10): 3902 - 3907. [Abstract] [Full Text]
|
|
|
|
|
|
S. T. Davidge, Y. Zhang, and K. G. Stewart A comparison of ovariectomy models for estrogen studies Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2001; 280(3): R904 - R907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Walker, K. D. Burroughs, B. Davis, K. Sowell, J. I. Everitt, and R. Fuchs-Young Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma Reproductive Sciences, July 1, 2000; 7(4): 249 - 256. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Prestwood, M. Gunness, D. B. Muchmore, Y. Lu, M. Wong, and L. G. Raisz A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2197 - 2202. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Komi and O. Lassila Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells Blood, May 1, 2000; 95(9): 2875 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hodges, J. S. Bergerson, D. S. Hunter, and C. L. Walker Estrogenic Effects of Organochlorine Pesticides on Uterine Leiomyoma Cells in Vitro Toxicol. Sci., April 1, 2000; 54(2): 355 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. COHEN, S. WATTS, A. SHAH, R. AKERS, and L. PLOUFFE Jr Uterine Effects of 3-Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60 Obstet. Gynecol., January 1, 2000; 95(1): 104 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. McDonnell Selective Estrogen Receptor Modulators (SERMs): A First Step in the Development of Perfect Hormone Replacement Therapy Regimen Reproductive Sciences, January 1, 2000; 7(1_suppl): S10 - S15. [Abstract] [PDF]
|
|
|
|
 |
|
 J. An, R. C. J. Ribeiro, P. Webb, J.-A. Gustafsson, P. J. Kushner, J. D. Baxter, and D. C. Leitman Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators PNAS, December 21, 1999; 96(26): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Norris, L. A. Paige, D. J. Christensen, C. Chang, M. R. Huacani, D. Fan, P. T. Hamilton, D. M. Fowlkes, and D. P. McDonnell Peptide Antagonists of the Human Estrogen Receptor Science, July 30, 1999; 285(5428): 744 - 746. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial JAMA, June 16, 1999; 281(23): 2189 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sato, C. H. Turner, T. Wang, M. D. Adrian, E. Rowley, and H. U. Bryant LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 1 - 7. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Turner, G. L. Evans, J. P. Sluka, M. D. Adrian, H. U. Bryant, C. H. Turner, and M. Sato Differential Responses of Estrogen Target Tissues in Rats Including Bone to Clomiphene, Enclomiphene, and Zuclomiphene Endocrinology, September 1, 1998; 139(9): 3712 - 3720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Clarkson, M. S. Anthony, and C. P. Jerome Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 721 - 726. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Grese, J. P. Sluka, H. U. Bryant, G. J. Cullinan, A. L. Glasebrook, C. D. Jones, K. Matsumoto, A. D. Palkowitz, M. Sato, J. D. Termine, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators PNAS, December 9, 1997; 94(25): 14105 - 14110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Gehm, J. M. McAndrews, P.-Y. Chien, and J. L. Jameson Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor PNAS, December 9, 1997; 94(25): 14138 - 14143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Paech, P. Webb, G. G. Kuiper, S. Nilsson, J. Gustafsson, P. J. Kushner, and T. S. Scanlan Differential Ligand Activation of Estrogen Receptors ER  and ER at AP1 SitesScience, September 5, 1997; 277(5331): 1508 - 1510. [Abstract] [Full Text]
|
|
|
|
|
|
J. An, C. Tzagarakis-Foster, T. C. Scharschmidt, N. Lomri, and D. C. Leitman Estrogen Receptor beta -Selective Transcriptional Activity and Recruitment of Coregulators by Phytoestrogens J. Biol. Chem., May 18, 2001; 276(21): 17808 - 17814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Zajchowski, K. Kauser, D. Zhu, L. Webster, S. Aberle, F. A. White III, H.-L. Liu, R. Humm, J. MacRobbie, P. Ponte, et al. Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints J. Biol. Chem., May 19, 2000; 275(21): 15885 - 15894. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
